Sunhawk Vision Biotech

Sunhawk Vision Biotech Gross Margin

Gross Margin of Sunhawk Vision Biotech (7759.TWO) as of Nov 14, 2026.

Gross Margin

-

Last updated:

Gross Margin of Sunhawk Vision Biotech is 2026 - . Gross Margin of Sunhawk Vision Biotech was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunhawk Vision Biotech Stock analysis

What does Sunhawk Vision Biotech do? Sunhawk Vision Biotech Inc, based in Kaohsiung, Taiwan, develops ophthalmic treatments. The company focuses on eye drops SHJ002 for myopia prevention in children, DED for dry eyes, and SJP for corneal damage in Sjogren's syndrome patients. With 15 employees, it operates through partnerships with pharmaceutical firms to secure regulatory approvals and technical collaborations globally. Listed on March 10, 2025, the company targets the global eye care market with its innovative drug portfolio. Sunhawk Vision Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunhawk Vision Biotech stock

On Eulerpool you can find the complete historical development of Gross Margin Sunhawk Vision Biotech since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sunhawk Vision Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunhawk Vision Biotech

All Key Metrics — Sunhawk Vision Biotech